| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | Alternate-Day Buprenorphine Administration. Phase I - 3 | ||||
| Official Title † | Alternate-Day Buprenorphine Administration. Phase I | ||||
| Brief Summary | The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects. |
||||
| Detailed Description | |||||
| Study Phase | Phase I | ||||
| Study Type † | Interventional | ||||
| Study Design † | Treatment, Double-Blind, Placebo Control, Crossover Assignment | ||||
| Primary Outcome Measure † | Drug use Opioid withdrawal Opioid agonist effects Dose identification Pupil diameter |
||||
| Secondary Outcome Measure † | |||||
| Condition † | Opioid-Related Disorders | ||||
| Intervention † | Drug: Buprenorphine | ||||
| MEDLINE PMIDs | 8164503 | ||||
| Links | |||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Completed | ||||
| Enrollment † | 0 | ||||
| Start Date † | April 1992 | ||||
| Completion Date | |||||
| Eligibility Criteria † | Please contact site for information. |
||||
| Gender | Both | ||||
| Ages | 28 Years to 45 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts †† | |||||
| Location Countries † | United States | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00000221 | ||||
| Organization ID | NIDA-06969-3 | ||||
| Secondary IDs †† | R01-06969-3 | ||||
| Study Sponsor † | National Institute on Drug Abuse (NIDA) | ||||
| Collaborators †† | University of Vermont | ||||
| Investigators † |
|
||||
| Information Provided By | National Institute on Drug Abuse (NIDA) | ||||
| Verification Date | November 1993 | ||||
| First Received Date † | September 20, 1999 | ||||
| Last Updated Date | June 23, 2005 | ||||
|
